- Home
- EDRY vs BEAT Comparison
EDRY vs BEAT Comparison
Compare EDRY & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDRY | BEAT |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | Greece | United States |
| Employees | N/A | 16 |
| Industry | Marine Transportation | Retail: Computer Software & Peripheral Equipment |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.6M | 53.2M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | EDRY | BEAT |
|---|---|---|
| Price | $24.30 | $0.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.63 |
| AVG Volume (30 Days) | 24.5K | ★ 525.4K |
| Earning Date | 06-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.30 | N/A |
| Revenue Next Year | $10.13 | $315.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.95 | $0.54 |
| 52 Week High | $28.00 | $4.00 |
Technical Indicators
Market Signals| Indicator | EDRY | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | 54.42 | 32.20 |
| Support Level | $18.21 | $0.54 |
| Resistance Level | $23.53 | $0.94 |
| Average True Range (ATR) | 1.60 | 0.05 |
| MACD | 0.10 | -0.01 |
| Stochastic Oscillator | 33.09 | 12.18 |
Price Performance
Historical ComparisonAbout EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.